New Antibody-Drug Conjugate Tested in Solid Tumor Study
A new phase 1 study is testing the safety of an experimental antibody-drug conjugate for patients with solid tumors.
Updated on Oct. 15, 2026 in Cancer
Live Poll
Should medical researchers prioritize new cancer treatments even when the targeted biological markers are kept undisclosed?
MacroGenics has initiated a Phase 1 study to evaluate the safety and preliminary activity of MGC030, a new antibody-drug conjugate. The trial is now enrolling patients with relapsed or refractory solid tumors.
Why it matters
This study represents an early-stage investigation into whether a new antibody-drug conjugate design can effectively treat patients whose solid tumors have not responded to existing therapies. Researchers are monitoring whether the drug is both tolerable and capable of initiating an antitumor response.
This Phase 1 dose-escalation trial is evaluating the safety, pharmacokinetics, and antitumor activity of MGC030 in up to 54 participants. As an early-stage trial, findings are preliminary and the antibody target remains undisclosed.
The players
MacroGenics
A Rockville-based biotechnology company focused on the development of antibody-based therapeutics for the treatment of cancer.
The details
MGC030 is an antibody-drug conjugate engineered with a cleavable exatecan-based cytotoxic payload designed to deliver therapy directly to cancer cells. It features a drug-to-antibody ratio of 4, a configuration intended to balance the drug's delivery mechanism. The multi-center trial employs an open-label design to assess safety and tolerability, with provisions to expand enrollment at specific dose levels.
Timeline
October 15, 2026: First patient dosed in the Phase 1 study of MGC030.
Health Landscape
This study represents the latest expansion of the MacroGenics clinical pipeline, which is currently testing its third antibody-drug conjugate in human trials. The research follows a broader industry shift toward using conjugate technologies to precisely deliver cytotoxic payloads to refractory solid tumors.
This early-stage study is limited to patients with specific relapsed or refractory solid tumors. Anyone considering trial participation should review the clinical status of their condition and discuss the risks and potential for enrollment with their oncology care team.
The takeaway
Early-phase trials like this one focus on establishing the safety of new delivery systems for cancer treatments. Patients with treatment-resistant tumors can speak with their oncologist about whether they meet the specific criteria for current clinical trials.
Further reading
Learn more about the latest research and trial developments in Cancer.
More information
For detailed study information, visit the clinical trials registry.
Live Poll
Should medical researchers prioritize new cancer treatments even when the targeted biological markers are kept undisclosed?
